Surgery – Instruments – Sutureless closure
Reexamination Certificate
1999-04-01
2002-10-01
Chaudhuri, Olik (Department: 2814)
Surgery
Instruments
Sutureless closure
Reexamination Certificate
active
06458147
ABSTRACT:
FIELD OF THE INVENTION
The invention generally relates systems and methods for arresting or controlling the bleeding or leakage of fluid in body tissues, e.g., diffuse organ bleeding, lung punctures, anastomotic leakage, and the like.
BACKGROUND OF THE INVENTION
Hemostatic barriers are routinely called upon to control bleeding. The bleeding may be caused by trauma, e.g. splenic, kidney, and liver lacerations, or may be caused during surgery, e.g. tumor removal or bone bleeding.
Bleeding is conventionally controlled by the application of solid sheets of material, e.g. gauze, Gelfoam™ material, or Surgicel™ material. These materials can be soaked with a hemostatic agent, such as thrombin or epinephrine, or sprayable formulations such as fibrin glue.
Conventional treatment modalities require the use of these hemostatic agents in conjunction with pressure to achieve hemostasis. The various hemostatic agents can include coagulation factors (e.g. thrombin), platelet activators (e.g. collagen), vasoconstrictors (epinephrine), or fibrinolytic inhibitors.
In some instances, conventional treatments achieve hemostasis in a clinically acceptable time. Still, there are a number of drawbacks.
For example, many treatment modalities consist of bovine collagen and bovine thrombin to cause the desired clotting action. These products have the potential for the transmission to humans of bovine spongiform encephalopathy (also called “Mad Cow Disease”). Regardless, the bovine thrombin marketed today is relatively impure, and these impurities can lead to complications in certain patient populations. Furthermore, fibrin glue, generally composed of purified fibrinogen and thrombin from pooled human blood, has safety and efficacy concerns as well. Additionally, many products do not achieve hemostasis in a clinically acceptable period, particularly in cases of brisk bleeding.
In addition to hemostatic agents, surgical sealants are also commonly used to control bleeding or fluid leakage along anastomoses formed by suture or staple lines, e.g., between blood vessels, bowel, or lung tissue. In cases of blood leakage, fibrin glue can be utilized to seal an anastomosis. Still, fibrin glue's lack of adhesion to moist tissue, safety concerns, and cost precludes its widespread use as a surgical sealant for blood vessel anastomoses.
Conventional hemostatic agents and surgical sealants for blood vessel anastomoses achieve hemostasis using the application of pressure and by activating the coagulation pathway of the blood. Yet, many of the surgeries where hemostatic barriers and surgical sealants are required also require the administration of anti-coagulation therapies, such as heparin. The hemostatic barrier or surgical sealant, which is promoting coagulation, is hindered by the effect of the heparin, which is preventing coagulation.
Despite conventional treatment modalities for hemostatic barriers and surgical sealants, there is a need for a biomaterial that safely, quickly, and reliably arrests or controls fluid leakage in body tissues through the application of pressure and without interaction with the patient's coagulation pathways.
SUMMARY OF THE INVENTION
The invention provides compositions, instruments, systems, and methods, which arrest or control bleeding or leakage of fluid in body tissue.
According to one aspect of the invention, a biocompatible and biodegradable material is provided which comprises a hydrogel compound free of a hemostatic agent and which, when applied by instruments, systems, and methods that embody the invention, arrests the flow of blood or fluid from body tissue.
According to another aspect of the invention, a biocompatible and biodegradable material is provided which comprises a hydrogel compound free of a hemostatic agent and which, when applied by instruments, systems, and methods that embody the invention,arrests organ diffuse bleeding.
According to another aspect of the invention, a biocompatible and biodegradable material is provided which comprises a protein solution and a polymer solution including a derivative of a hydrophilic polymer with a functionality of at least three, which, when mixed by instruments, systems, and methods that embody the invention, form a mechanical non-liquid covering structure that arrests the flow of blood or seals tissue.
Features and advantages of the inventions are set forth in the following Description and Drawings, as well as in the appended claims.
REFERENCES:
patent: 4101380 (1978-07-01), Rubinstein et al.
patent: 4161948 (1979-07-01), Bichon
patent: 4464468 (1984-08-01), Avrameas et al.
patent: 4839345 (1989-06-01), Doi et al.
patent: 5051406 (1991-09-01), Satoh
patent: 5129882 (1992-07-01), Weldon et al.
patent: 5207670 (1993-05-01), Sinofsky
patent: 5252714 (1993-10-01), Harris et al.
patent: 5318524 (1994-06-01), Morse et al.
patent: 5383896 (1995-01-01), Gershony et al.
patent: 5403278 (1995-04-01), Ernst et al.
patent: 5410016 (1995-04-01), Hubbell et al.
patent: 5419765 (1995-05-01), Weldon et al.
patent: 5514379 (1996-05-01), Weissleder et al.
patent: 5520885 (1996-05-01), Coelho et al.
patent: 5529577 (1996-06-01), Hammerslag
patent: 5567435 (1996-10-01), Hubbell et al.
patent: 5583114 (1996-12-01), Barrows et al.
patent: 5601602 (1997-02-01), Fowler
patent: 5626601 (1997-05-01), Gershony et al.
patent: 5626863 (1997-05-01), Hubbell et al.
patent: 5653730 (1997-08-01), Hammerslag
patent: 5672662 (1997-09-01), Harris et al.
patent: 5676689 (1997-10-01), Kensey et al.
patent: 5725498 (1998-03-01), Janzen et al.
patent: 5733563 (1998-03-01), Fortier
patent: 5739208 (1998-04-01), Harris
patent: 5759194 (1998-06-01), Hammerslag
patent: 5782860 (1998-07-01), Epstein et al.
patent: 5791352 (1998-08-01), Reich et al.
patent: 5824015 (1998-10-01), Sawyer
patent: 5843124 (1998-12-01), Hammerslag
patent: 5844016 (1998-12-01), Sawhney et al.
patent: 5858746 (1999-01-01), Hubbell et al.
patent: 5874500 (1999-02-01), Rhee et al.
patent: 5900245 (1999-05-01), Sawhney et al.
patent: 5900461 (1999-05-01), Harris
patent: 5922009 (1999-07-01), Epstein et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5935147 (1999-08-01), Kensey et al.
patent: 5936035 (1999-08-01), Rhee et al.
patent: 5942209 (1999-08-01), Leavitt et al.
patent: 5951583 (1999-09-01), Jensen et al.
patent: 5951589 (1999-09-01), Epstein et al.
patent: 5986043 (1999-11-01), Hubbell et al.
patent: 5990237 (1999-11-01), Bentley et al.
patent: 6007613 (1999-12-01), Izoret
patent: 6022361 (2000-02-01), Epstein et al.
patent: 6051248 (2000-04-01), Sawhney et al.
patent: 6060582 (2000-05-01), Hubbell et al.
patent: 6083524 (2000-07-01), Sawhney et al.
patent: 6152943 (2000-11-01), Sawhney
patent: 6162241 (2000-12-01), Coury et al.
patent: 6165201 (2000-12-01), Sawhney et al.
patent: 6177095 (2001-01-01), Sawhney et al.
patent: 6179862 (2001-01-01), Sawhney
patent: WO 96/11671 (1996-04-01), None
patent: WO 97/22371 (1997-06-01), None
patent: WO 99/07417 (1999-02-01), None
patent: WO 99/14259 (1999-03-01), None
patent: WO 99/45964 (1999-09-01), None
patent: WO 00/09087 (2000-02-01), None
patent: WO 00/09199 (2000-02-01), None
patent: WO 00/33764 (2000-06-01), None
patent: WO 00/62827 (2000-10-01), None
West JL et al Proteolytically Degradable Hydrogels Apr. 30-May 4, 1997 23rdAnr the Society for Biomaterials New Orleans Louisiana.
Cruise Gregory M
Hnojewyj Olexander
Chaudhuri Olik
NeoMend, Inc.
Ryan Kromholz & Manion S.C.
Trinh (Vikki) Hoa
LandOfFree
Compositions, systems, and methods for arresting or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions, systems, and methods for arresting or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions, systems, and methods for arresting or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2957282